Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Grant and collaboration revenue	$ 0	$ 30,414	$ 81,526	$ 220,539
Operating expenses:
Research and development	2,721,196	1,224,362	5,358,917	2,659,980
General and administrative	1,249,337	757,432	3,363,672	2,562,641
Total operating expenses	3,970,533	1,981,794	8,722,589	5,222,621
Loss from operations	(3,970,533)	(1,951,380)	(8,641,063)	(5,002,082)
Other income (expense):
Interest income	2,431	877	3,747	3,998
Interest expense	0	0	0	(1,286)
Gain on debt extinguishment	0	0	0	172,056
Total other income (expense)	2,431	877	3,747	174,768
Net loss	$ (3,968,102)	$ (1,950,503)	$ (8,637,316)	$ (4,827,314)
Basic and diluted:
Net loss per common share (in dollars per share)	$ (0.17)	$ (0.31)	$ (0.63)	$ (0.80)
Weighted average shares outstanding (in shares)	23,461,665	6,349,297	13,818,315	6,005,032